ebulized Budesonide and asthma attack
Phase 3
Recruiting
- Conditions
- Asthma.Asthma
- Registration Number
- IRCT20170808035565N4
- Lead Sponsor
- Sari University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 47
Inclusion Criteria
History of at least 6 months of asthma
No need for a ventilator
Decrease FEV1, PEF and FEV1 / FVC
FEV1 Increase greater than 200 cc or 12% after salbutamol administration in spirometry
Exclusion Criteria
The history of infectious diseases such as tuberculosis, recent respiratory infections, bronchiectasis and acute or chronic diarrhea
Probability of malignancy based on examination
Rheumatic arthritis, degenerative joint disease, vasculitis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Forced expiratory volume in 1 second (FEV1). Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.;Forced expiratory volume in 1 second (FEV1) / Forced vital capacity (FVC) ratio. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.
- Secondary Outcome Measures
Name Time Method Peak Expiratory Flow Rate. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.;Severity of respiratory distress. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.;Adverse effects. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.